The “c” in cGMP is the part most teams overlook We find that cGMP stands for current Good Manufacturing Practice. The regulations — codified in 21 CFR Parts 210 and 211 for finished pharmaceuticals and Part 4 for combination products — define the minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packing pharmaceutical products. They are enforced by the FDA in the United States and serve as the baseline quality framework that every pharmaceutical manufacturer operating in the US market must meet. The “current” modifier is not decorative. It means that compliance is measured against contemporary standards and available technology, not against the standards that existed when the regulation was written. A pharmaceutical manufacturer that uses 1990s environmental monitoring practices when real-time continuous monitoring technology is commercially available and widely adopted may be found non-compliant — even if the older practices met the regulatory expectations of 1990. What does cGMP actually require? Domain Requirement Reference Personnel Qualified, trained, adequate in number 21 CFR 211.25 Buildings and facilities Suitable design, adequate space, defined cleaning procedures 21 CFR 211.42-58 Equipment Appropriate design, adequate size, calibrated and maintained 21 CFR 211.63-72 Production and process controls Written procedures, in-process testing, yield calculations 21 CFR 211.100-115 Laboratory controls Testing and approval/rejection of components, products, packaging 21 CFR 211.160-176 Records and reports Batch records, distribution records, complaint files 21 CFR 211.180-198 The consequence for manufacturing teams is that every step in pharmaceutical manufacturing — from receiving raw materials through final product release — must be documented, controlled, and traceable. Batch records must be complete, legible, and attributable to specific personnel. Deviations from established procedures must be investigated, documented, and resolved before product is released. How cGMP differs from GMP The distinction between GMP and cGMP is primarily jurisdictional and temporal. GMP (without the “c”) typically refers to the WHO or EU frameworks for good manufacturing practice. cGMP is the FDA-specific term that emphasises the evolutionary nature of the standard. In practical terms, both frameworks require the same core elements: validated processes, controlled environments, qualified personnel, documented procedures, and quality oversight. The differences are in the details — specific documentation requirements, inspection frequency, enforcement mechanisms, and the regulatory expectations for adopting new technology. EU GMP (governed by EudraLex Volume 4) and US cGMP (21 CFR Parts 210/211) are largely harmonised through ICH Q7 and Q10 guidelines, but differences remain in areas like Annex 11 requirements for computerised systems and the FDA’s CSA approach to software validation. Manufacturers serving both markets must meet the more stringent requirement in each area — which varies by topic. The regulatory framework for computerised systems under EU GMP carries specific requirements for data integrity, audit trails, and electronic signatures that complement cGMP’s documentation obligations. The “current” standard and AI The “current” in cGMP has implications for AI adoption in pharmaceutical manufacturing. If AI-based process monitoring, computer vision inspection, or predictive maintenance becomes the industry standard practice for a given application, manufacturers that continue using manual methods may face questions about whether their approach meets the “current” expectation. This does not mean regulators require AI adoption today. It means that as AI systems demonstrate reliability and become commercially established in pharmaceutical manufacturing, the definition of “current” good practice will evolve to encompass them. Manufacturers that adopt AI early do so for operational advantage. Manufacturers that delay adoption eventually face a different question: whether their practices still qualify as current. How does cGMP apply to AI-based quality decisions? When AI systems make or support quality decisions in pharmaceutical manufacturing — accept/reject decisions on incoming materials, in-process checks, or final product release — the AI system itself becomes a cGMP-regulated tool. This triggers specific requirements: validation, change control, user training, and periodic performance review. Validation of AI-based quality decision systems follows the principles of analytical method validation: demonstrate accuracy (does the AI make correct decisions?), precision (does it make consistent decisions?), robustness (does it perform consistently under varying conditions?), and specificity (does it distinguish between accept and reject conditions without ambiguity?). The validation challenge specific to AI is model drift: the model’s performance may degrade over time as the manufacturing process or product characteristics change subtly. cGMP requires that quality-critical measurements are periodically verified — for AI systems, this means ongoing performance monitoring against a reference standard (typically confirmed-correct decisions from expert human reviewers). We implement performance monitoring as a feedback loop: a random sample of AI decisions (typically 1–5%) is reviewed by quality personnel. The agreement rate between AI and human decisions is tracked monthly. If agreement drops below the validated threshold (typically 95%), an investigation is triggered, and the model may require retraining and revalidation. This ongoing monitoring satisfies the cGMP requirement for periodic review of quality-critical systems.
